Get the latest news, insights, and market updates on SPRY (ARS Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg
ARS Pharmaceuticals (SPRY) announced that the National Medical Products Administration in China has granted approval for neffy 2 mg for the emergency treatment of Type 1 allergic reactions in adults and children who weigh 30 kg or more. ARS Pharma and Pediatrix Therapeutics anticipate filing for approval of neffy 1 mg dose for children greater than 15 kg and less than 30 kg in the coming months. ARS Pharma entered into an exclusive licensing agreement with Pediatrix Therapeutics in 2021, providi Dec 30, 2025 - $SPRY
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market neffy in China under the trade name 优敏速®, expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their Dec 29, 2025 - $SPRY
How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts
ARS Pharmaceuticals has seen its fair value estimate lowered from $30.00 to $28.67 per share, reflecting new analyst research and slightly more cautious market sentiment. This change comes alongside a modest increase in the discount rate from 7.33% to 7.35% and a downward revision of revenue growth expectations from 47.06% to 45.36%. As analyst perspectives continue to evolve with developments for ARS Pharmaceuticals, stay tuned to learn how you can monitor and respond to shifts in the... Dec 1, 2025 - $SPRY
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025, in New York. Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in a fir Nov 26, 2025 - $SPRY
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks
ARS Pharmaceuticals stock has seen its consensus analyst price target decline slightly, dropping from $31.00 to $30.00 per share. This modest adjustment reflects a balance between optimism regarding strong product growth and caution related to ongoing market challenges. Stay tuned to discover how shifting analyst perspectives could impact your outlook on the ARS Pharmaceuticals story going forward. Stay updated as the Fair Value for ARS Pharmaceuticals shifts by adding it to your watchlist or... Nov 17, 2025 - $SPRY
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing experience Strong balance sheet of $288.2 million cash, cash equivalents and short-term investments anticipated to fund operations through cash-flow break-even Conference call to be held today, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. Nov 10, 2025 - $SPRY
ARS Pharma SPRY Q3 2025 Earnings Call Transcript
Richard Lowenthal: Thank you, Justin. Good morning, everybody, and thank you for joining us to discuss what has been a pivotal quarter for ARS Pharmaceuticals, driven by the continued momentum of Nephi in the U.S. and around the world. As you can see on Slide three, U.S. net product revenue for Nephi grew again quarter over quarter, reaching $31.3 million in Q3, representing a 2.5-fold increase from the prior quarter and exceeding consensus expectations of $28.3 million. Nov 10, 2025 - $SPRY
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple